Metabolic Dysfunction-Associated Steatotic Liver Disease References

Last updated: 08 August 2024
  1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-2023. doi: 10.1002/hep.25762. Accessed 4 Nov 2016. PMID: 22488764
  2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-1402. doi: 10.1016/j.jhep.2015.11.004. Accessed 4 Nov 2016. PMID: 27062661
  3. Iser D, Ryan M. Fatty liver disease - a practical guide for GPs. Aust Fam Physician. 2013 Jul;42(7):444-447. http://www.racgp.org.au. Accessed 4 Nov 2016. PMID: 23826593
  4. LaBrecque DR, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014 Jul;48(6):467-473. doi: 10.1097/MCG.0000000000000116. Accessed 4 Nov 2016. PMID: 24921212
  5. National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE. www.nice.org.uk. Jul 2016. Accessed 4 Nov 2016.
  6. Torres DM, Harrison SA. Nonalcoholic fatty liver disease. In: Feldman M, Friedman L, Brandt L, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed: Saunders, an imprint of Elsevier Inc; 2016. Accessed 4 Nov 2016:1428-1440.
  7. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015 Apr;50(4):364-377. doi: 10.1007/s00535-015-1050-7. Accessed 4 Nov 2016. PMID: 25708290
  8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Accessed 29 May 2018. PMID: 28714183
  9. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020 Jan;71(1):306-333. doi: 10.1002/hep.30866. Accessed 16 Jan 2020. PMID: 31314133
  10. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Accessed 16 Jan 2020. PMID: 29628280
  11. Kanazawa I, Tanaka K, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit. 2014 Sep;20:1662-1667. doi: 10.12659/MSM.890989. PMID: 25228119
  12. Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016 Feb;4(2):183-187. doi: 10.3892/br.2016.569. PMID: 26893835
  13. Boccatonda A, Andreetto L, D’Ardes D, et al. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. Biomedicines. 2023 Mar;11(3):833. doi: 10.3990/biomedicines11030883. Accessed 23 Jun 2023
  14. Chan WK, Tan SS, Chan SP, et al. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. PMID: 35080048
  15. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Accessed 23 Jun 2023. PMID: 33006093
  16. Gallego-Durán R, Albillos A, Ampuero J, et al. Metabolic-associated fatty liver disease: from simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol. 2022 Nov;45(9):724-734. doi: 10.1016/j.gastrohep.2022.02.005. Accessed 23 Jun 2023. PMID: 35248669
  17. Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Tansl Hepatol. 2022 Apr;10(2):329-338. doi: 10.14218/JCTH.2021.00178. Accessed 23 Jun 2023. PMID: 35528971
  18. Ng CH, Huang DQ, Nguyen MH. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: prevalence, outcomes and implications of a change in name. Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. PMID: 35545437
  19. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med. 2023 Jun;18(4):993-1006. doi: 10.1007/s11739-023-03203-0. PMID: 36807050
  20. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Accessed 36727674. PMID: 36727674
  21. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on a new fatty liver disease nomenclature. Hepatology. 2023 Jun. doi: 10.1097/HEP.0000000000000520. Accessed 14 Jul 2023. PMID: 37363821
  22. Sheth SG, Chopra S. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. UpToDate. https://www.uptodate.com. 07 Nov 2022.
  23. Tacke F, Canbay A, Bantel H, et al. Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021-025. Z Gastroenterol. 2022 Sep;60(9):1346-1421. doi: 10.1055/a-1880-2283. PMID: 36100202
  24. Zhou XD, Cai J, Targher G, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022 Dec;21(1):270. doi: 10.1186/s12933-022-01697-0. PMID: 36463192